Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Shares Repurchased (2020 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Preferred Shares Repurchased for 3 consecutive years, with $3.7 million as the latest value for Q1 2025.

  • Quarterly Preferred Shares Repurchased fell 43.95% to $3.7 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Oct 2025, down 89.35% year-over-year, with the annual reading at $22.5 million for FY2025, 39.15% up from the prior year.
  • Preferred Shares Repurchased for Q1 2025 was $3.7 million at PharmaCyte Biotech, down from $9.3 million in the prior quarter.
  • The five-year high for Preferred Shares Repurchased was $9.5 million in Q2 2024, with the low at $3.7 million in Q1 2025.